Loading company…
Riskpilot
← Back to search
Sign in
Get full access
NEUROINNOVATECH ApS
APS
Active
CVR 44482096
Vandtårnsvej 62A, 1. b
Manufacture of pharmaceutical preparations · NACE 2120
Est. 2023
— employees
www.neuroinnovatech.com
Watchlist
Share
Download PDF
Full Risika report
Overview
Financials
People & ownership
Related companies
Revenue 2025
DKK -220K
EBITDA margin
100.0%
Equity ratio
38.7%
Financial strength
Net profit 2025
DKK -237K
EBITDA — year on year
DKK millions
0M
0M
1M
1M
1M
0M
2025
Key figures
Annual report 2025
Revenue
DKK -220K
—
EBITDA
DKK -220K
—
Net profit
DKK -237K
—
Total assets
DKK 2,4M
—
Equity
DKK 923K
—
Employees
—
—
Company information
Legal name
NEUROINNOVATECH ApS
CVR number
44482096
Legal form
Anpartsselskab
NACE code
2120 · Manufacture of pharmaceutical preparations
Founded
28. november 2023
Share capital
DKK 183.875
Employees
—
VAT registered
Yes
Audit selected
Yes
Last report
2025-04-30
Financial year
January – December
Signatory rights
Selskabet tegnes af direktionen i forening.
Company purpose
Selskabets formål er at udvikle repositionerede lægemidler samt dermed beslægtet virksomhed.
Contact
Address
Vandtårnsvej 62A, 1. b
Phone
+4542901733
Email
info@neuroinnovatech.com
Website
www.neuroinnovatech.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
Visit risika.com
Explore
Companies in Manufacture of pharmaceutical preparations
Companies in Gladsaxe
All Denmark companies
Revenue
DKK millions
0M
0M
1M
1M
1M
0M
2025
EBITDA
DKK millions
0M
0M
1M
1M
1M
0M
2025
Income statement
DKK thousands
Item
2025
Revenue
-220
Staff expenses
-0
EBITDA
-220
Depreciation & amort.
-17
EBIT
-237
Net financials
0
Profit before tax
-237
Tax
-0
Net profit
-237
Balance sheet
DKK thousands
Item
2025
Total assets
2.384
Equity
923
Long-term debt
0
Short-term debt
1.461
Total debt
1.461
Financial ratios
5-year trend
EBITDA margin
-21999300.0%
This company
15.8%
Market median
-139236176% vs market
2025
2025
Equity ratio
38.7%
This company
38.2%
Market median
+1% vs market
2025
2025
Return on equity
-25.6%
This company
18.4%
Market median
-239% vs market
2025
2025
Net profit margin
-23666100.0%
This company
8.1%
Market median
-292174174% vs market
2025
2025
Asset turnover
-0.09×
This company
1.12×
Market median
-108% vs market
2025
2025
Debt / equity
1.58×
This company
0.62×
Market median
-155% vs market
2025
2025
Annual reports & filings
Annual report 2025
Filed via CVR / Virk · Period 2023-11-28 – 2025-04-30
View
PDF
Management
Actively employed in the business
Name
Role
Member since
Age
Other directorships
TG
Tom Glæsner Larsen
Management
Management
2023
—
—
CT
Christian Torben Hill-Madsen
Management
Management
2024
—
—
AT
Allan Traugott Wehnert
Management
Management
2024
—
—
Board of directors
Non-executive oversight
Name
Role
Member since
Age
Other directorships
KL
Kiri Lillan Glæsner
Board of Directors
2024
—
—
Shareholders
As of last annual report
Shareholder
Type
Ownership
Votes
Since
ABCHill Holding ApS
Company
10.0%
10.0%
2024
Alteral Therapeutics ApS
Company
10.0%
10.0%
2025
GK PARTNERS ApS
Company
10.0%
10.0%
2025
AC Nordic ApS
Company
5.0%
5.0%
2025
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive.
Learn more
.
Company hierarchy
Wehnert Holding ApS
Alteral Therapeutics ApS
NEUROINNOVATECH ApS
(this company)
Board network connections
Board members of NEUROINNOVATECH ApS also hold positions in
0
other companies.
Person
Role here
Other companies
Tom Glæsner Larsen
Management
0 companies
Christian Torben Hill-Madsen
Management
0 companies
Allan Traugott Wehnert
Management
0 companies
Kiri Lillan Glæsner
Board of Directors
0 companies